Current Promotions

No active promotions at the moment. Check back later for special offers!

No video available

Get in Touch

Call Now Visit Website

About

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space.

AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel.

ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d'Hebron Institut d'Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard).

ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic.

The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma.

ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA.

Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Keywords

No keywords available

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No FAQs available for this business.

Reviews

No reviews yet. Be the first to review!

Social Links

No social media links available

Photo Gallery

No photos available

Business Info

23
2009
$5.4M

Business Hours

Business hours not available

Own This Business?

Unclaimed

Take control of your business page to update information, respond to reviews, and more.

Claim This Business